Moderna Inc
Change company Symbol lookup
Select an option...
MRNA Moderna Inc
TDS-U Telephone and Data Systems Inc
TPR Tapestry Inc
BGRY Berkshire Grey Inc
BKNG Booking Holdings Inc
UHT Universal Health Realty Income Trust
BBVA Banco Bilbao Vizcaya Argentaria SA
RILY B Riley Financial Inc
WTS Watts Water Technologies Inc
MMM 3M Co
Go

Health Care : Biotechnology | Large Cap Blend
Company profile

Moderna, Inc. is a biotechnology company that is focused on creating a transformative medicines based on messenger ribonucleic acid (mRNA), to improve the lives of patients. The Company’s mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane, or secreted proteins that have a therapeutic or preventive benefit with the potential to address a range of spectrum of diseases. It is developing vaccines and therapeutics for infectious diseases, immuno-oncology, rare diseases, autoimmune and cardiovascular diseases, independently and with its strategic collaborators. The Company develops technologies that enable the development of mRNA medicines for diverse applications. It has created modalities, including prophylactic vaccines, systemic secreted and cell surface therapeutics, cancer vaccines, intratumoral immuno-oncology, and systemic intracellular therapeutics. The Company develops technologies that enable the development of mRNA medicines.

Closing Price
$173.25
Day's Change
-3.10 (-1.76%)
Bid
--
Ask
--
B/A Size
--
Day's High
178.74
Day's Low
172.40
Volume
(Below Average)
Volume:
2,821,351

10-day average volume:
3,521,279
2,821,351

Display:

Providers:

UpdateCancel
6 providers
January 30, 2023
Moderna Granted FDA Breakthrough Therapy Designation for mRNA-1345, An Investigational Respiratory Syncytial Virus (RSV) Vaccine Candidate

Designation based on positive topline data from the ConquerRSV Phase 3 pivotal efficacy trial, which demonstrated vaccine efficacy of 83.7% against RSV lower respiratory tract disease, defined by 2 or more symptoms in older adults (Accesswire)

January 18, 2023
Thinking about trading options or stock in Moderna, United Airlines, Interactive Brokers, McDonald's, or Chevron?

InvestorsObserverissues critical PriceWatch Alerts for MRNA, UAL, IBKR, MCD, and CVX. https://mma.prnewswire.com/media/1333368/InvestorsObserver_Logo.jpg Click a link below then choose between in-depth options trade idea report or a stock score...(PR Newswire)

January 17, 2023
Moderna Announces mRNA-1345, an Investigational Respiratory Syncytial Virus (RSV) Vaccine, Has Met Primary Efficacy Endpoints in Phase 3 Trial in Older Adults

mRNA-1345 demonstrated vaccine efficacy of 83.7% against RSV lower respiratory tract disease, defined by 2 or more symptoms in older adults mRNA-1345 was generally well-tolerated, with no safety concerns identified by the DSMB (Accesswire)

January 09, 2023
Moderna Announces Advances Across mRNA Pipeline and Provides Business Update

COVID-19 vaccine sales for 2022 approximately $18.4 billion (unaudited) Reiterating 2023 expected minimum COVID-19 vaccine sales of approximately $5.0 billion; continue to expect additional contracts for 2023 (Accesswire)

January 05, 2023
Moderna and CytomX Announce Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics

Collaboration will combine Moderna's mRNA technology with CytomX's Probody® Platform to generate and develop therapeutics for oncology and non-oncology conditions CytomX to receive $35 million upfront payment with the potential for additional...(Accesswire)

January 04, 2023
Moderna to Acquire OriCiro Genomics

OriCiro's synthetic biology and enzyme technologies will support Moderna's expanding portfolio of therapeutics and vaccines Acquisition will bolster Moderna's suite of platform technologies (Accesswire)

January 03, 2023
Moderna to Provide Business and Pipeline Updates at the 2023 J.P. Morgan Healthcare Conference

CAMBRIDGE, MA / ACCESSWIRE / January 3, 2023 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that CEO Stéphane Bancel will present an update on the Company and its...(Accesswire)

December 21, 2022
Moderna Finalizes Strategic Partnership with UK Government

Facility to enable access to domestically manufactured mRNA respiratory vaccines, pending regulatory assessment and licensure The ten-year strategic partnership is expected to provide the UK public with response capabilities to ensure future...(Accesswire)

December 20, 2022
Chantal Friebertshauser Joins Moderna as Senior Vice President, Commercial

Newly created role will have responsibility for commercial efforts in Europe, Middle East and Canada CAMBRIDGE, MA / ACCESSWIRE / December 20, 2022 / Moderna, Inc . (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA)...(Accesswire)

December 19, 2022
Thinking about trading options or stock in Madrigal Pharmaceuticals, Amazon, Moderna, Apple, or Baidu?

InvestorsObserverissues critical PriceWatch Alerts for MDGL, AMZN, MRNA, AAPL, and BIDU. https://mma.prnewswire.com/media/1333368/InvestorsObserver_Logo.jpg Click a link below then choose between in-depth options trade idea report or a stock score...(PR Newswire)

December 16, 2022
EMA Committee for Medicinal Products for Human Use (CHMP) Recommends the Use of Moderna's BA.1 Targeting Bivalent COVID-19 Booster in Children (6-11 Years) In the European Union

The recommendation is based on clinical data for Moderna's bivalent Omicron-targeting COVID-19 vaccine, mRNA.1273.214 Moderna's bivalent Omicron-targeting COVID-19 vaccines (mRNA.1273.214 (BA.1) & mRNA.1273.222 (BA.4-5)) are approved for...(Accesswire)

December 15, 2022
Thinking about trading options or stock in Ambarella, Apple, Jabil, Moderna, or Monster Beverage?

InvestorsObserverissues critical PriceWatch Alerts for AMBA, AAPL, JBL, MRNA, and MNST. https://mma.prnewswire.com/media/1333368/InvestorsObserver_Logo.jpg Click a link below then choose between in-depth options trade idea report or a stock score...(PR Newswire)

Circle Pharma Appoints Stephen Kelsey, MB ChB, MD, to its Board of Directors

Circle Pharma, a company focused on developing macrocycle therapeutics against targets previously considered to be undruggable, has appointed Stephen Kelsey as an independent member of its Board of Directors. Dr. Kelsey has extensive experience in...(BusinessWire)

December 14, 2022
Thinking about trading options or stock in Block, Moderna, Apple, Activision Blizzard, or General Electric?

InvestorsObserverissues critical PriceWatch Alerts for SQ, MRNA, AAPL, ATVI, and GE. https://mma.prnewswire.com/media/1333368/InvestorsObserver_Logo.jpg Click a link below then choose between in-depth options trade idea report or a stock score...(PR Newswire)

December 13, 2022
Thinking about trading options or stock in Moderna, Docusign, Trade Desk, Apple, or Oracle?

InvestorsObserverissues critical PriceWatch Alerts for MRNA, DOCU, TTD, AAPL, and ORCL. https://mma.prnewswire.com/media/1333368/InvestorsObserver_Logo.jpg Click a link below then choose between in-depth options trade idea report or a stock score...(PR Newswire)

Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination with KEYTRUDA(R) (pembrolizumab), Met Primary Efficacy Endpoint in Phase 2b KEYNOTE-942 Trial

mRNA-4157/V940, in combination with KEYTRUDA, demonstrated a statistically significant and clinically meaningful reduction in the risk of disease recurrence or death compared to KEYTRUDA monotherapy in stage III/IV melanoma patients with high risk...(Accesswire)

December 08, 2022
Moderna Receives FDA Emergency Use Authorization for Omicron-Targeting Bivalent COVID-19 Booster Vaccine in Children 6 Months Through 5 Years of Age

mRNA-1273.222 Targets the BA.4/BA.5 Strains of Omicron Variant Authorization Is Based Upon Clinical and Pre-Clinical Data for Moderna's Bivalent Vaccines CAMBRIDGE, MA / ACCESSWIRE / December 8, 2022 / Moderna, Inc. (NASDAQ:MRNA), a...(Accesswire)

December 07, 2022
Brad Miller Joins Moderna as Chief Information Officer

Current Chief Digital Officer, Marcello Damiani, to retire in March CAMBRIDGE, MA / ACCESSWIRE / December 7, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced...(Accesswire)

November 29, 2022
Moderna to Present at the Piper Sandler 34th Annual Healthcare Conference

CAMBRIDGE, MA / ACCESSWIRE / November 29, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced its participation in a fireside chat at the Piper Sandler 34th Annual...(Accesswire)

Next >

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.